4,021 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 4,021 shares of the specialty pharmaceutical company’s stock, valued at approximately $931,000.

Several other institutional investors have also modified their holdings of JAZZ. Bank of New York Mellon Corp boosted its holdings in shares of Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after buying an additional 517,514 shares in the last quarter. Bank of America Corp DE grew its position in shares of Jazz Pharmaceuticals by 10.9% in the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after buying an additional 99,656 shares during the last quarter. Systematic Financial Management LP raised its stake in Jazz Pharmaceuticals by 2.6% during the 1st quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after acquiring an additional 10,237 shares in the last quarter. Quantinno Capital Management LP raised its stake in Jazz Pharmaceuticals by 9.7% during the 1st quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock worth $36,163,000 after acquiring an additional 16,928 shares in the last quarter. Finally, Tri Locum Partners LP acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth $29,995,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $234.66 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.58 and a current ratio of 1.82. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The firm has a 50-day simple moving average of $230.15 and a 200-day simple moving average of $217.11. The company has a market capitalization of $15.06 billion, a price-to-earnings ratio of 79.82, a price-to-earnings-growth ratio of 0.46 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating the consensus estimate of ($4.03) by $0.15. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the business posted $8.13 EPS. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current year.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 revenue and earnings expectations, with growth in oncology and rare sleep products cited as drivers. The company raised its 2026 revenue outlook to roughly $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Q3 earnings and outlook
• Positive Sentiment: The company announced a $500 million share buyback, which may support shareholder returns and provide demand for the stock. Share buyback announcement
• Positive Sentiment: Several analysts raised their price targets and maintained bullish ratings after the results, including JPMorgan, Morgan Stanley, RBC and Barclays. Analyst insights
• Neutral Sentiment: Director Bruce Cozadd sold 6,000 shares under a pre-arranged Rule 10b5-1 plan, reducing his position by 1.73%; he retained 339,875 shares after the sale. SEC filing
• Negative Sentiment: Some coverage cautioned that slowing growth and an Actiq-related charge could temper the positive effect of the earnings beat and improved guidance. Earnings outlook risks

Analyst Ratings Changes

Several equities analysts have issued reports on JAZZ shares. Needham & Company LLC upped their price objective on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft boosted their target price on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. Weiss Ratings cut Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. Wells Fargo & Company upped their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $337.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $293.45.

Insider Activity

In other news, EVP Robert Iannone sold 76,921 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the transaction, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. The trade was a 53.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the transaction, the director owned 339,875 shares in the company, valued at approximately $73,358,620. This trade represents a 1.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 100,121 shares of company stock worth $24,632,962 over the last quarter. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.